Get started
Author

Larissa S. Carnevalli

Observed names: Carnevalli, Larissa, Carnevalli, Larissa S, Carnevalli, Larissa S., L Carnevalli, L. Carnevalli, Larissa Carnevalli, Larissa S Carnevalli, Larissa S. CARNEVALLI, Larissa S. Carnevalli
Observed institutions: AstraZeneca (United Kingdom), University of Bradford, German Cancer Research Center, Heidelberg Institute for Stem Cell Technology and Experimental Medicine, University of Cincinnati, Universidade Federal de São Paulo
ORCID: 0000-0001-7432-0195
Observed ORCID: 0000-0001-7432-0195
OpenAlex ID: A5013351397
Myc Depletion Induces a Pluripotent Dormant State Mimicking Diapause
2016 · Roberta Scognamiglio, Nina Cabezas-Wallscheid, et al. · Cell · 271
PDF
S6K1 Plays a Critical Role in Early Adipocyte Differentiation
2010 · Larissa S. Carnevalli, Kouhei Masuda, et al. · Developmental Cell · 204
PDF
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
2018 · Chrysiis Michaloglou, Claire Crafter, et al. · Molecular Cancer Therapeutics · 177
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery
2019 · Molly A. Taylor, Adina M. Hughes, et al. · Journal for ImmunoTherapy of Cancer · 98
PDF
mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma
2012 · Hala Elnakat Thomas, Carol A. Mercer, et al. · Science Translational Medicine · 92
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
2018 · Larissa S. Carnevalli, Charles Sinclair, et al. · Journal for ImmunoTherapy of Cancer · 90
PDF
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
2022 · Alexey Revenko, Larissa S Carnevalli, et al. · Journal for ImmunoTherapy of Cancer · 89
PDF
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
2023 · Mandy Lawson, Natalie Cureton, et al. · Cancer Research · 71
PDF
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
2024 · Elizabeth L. Hardaker, Emilio Sanseviero, et al. · Nature Communications · 67
PDF
Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML
2020 · Silvia Basilico, Xiaonan Wang, et al. · Nature Communications · 58
PDF
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
2021 · Dimitra Georgopoulou, Maurizio Callari, et al. · Nature Communications · 56
PDF
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2020 · Theresa A. Proia, Maneesh Singh, et al. · Clinical Cancer Research · 55
PDF
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer
2018 · Alvaro Avivar-Valderas, Robert McEwen, et al. · Oncotarget · 51
PDF
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
2018 · Sophie Langdon, Adina Hughes, et al. · OncoImmunology · 51
Translation initiation at non-AUG codons mediated by weakened association of eukaryotic initiation factor (eIF) 2 subunits
2002 · Nilce N. HASHIMOTO, Larissa S. CARNEVALLI, et al. · Biochemical Journal · 47
PDF
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
2022 · Alison Harrod, Chun-Fui Lai, et al. · Oncogene · 45
PDF
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
2022 · Filipe Correia Martins, Dominique-Laurent Couturier, et al. · Nature Communications · 38
PDF
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach
2021 · Timothy I. Johnson, Christopher J. Minteer, et al. · EBioMedicine · 29
Phosphorylation of the α subunit of translation initiation factor-2 by PKR mediates protein synthesis inhibition in the mouse brain during status epilepticus
2006 · Larissa S. Carnevalli, Catia M. Pereira, et al. · Biochemical Journal · 29
Improved HSC reconstitution and protection from inflammatory stress and chemotherapy in mice lacking granzyme B
2014 · Larissa S. Carnevalli, Roberta Scognamiglio, et al. · The Journal of Experimental Medicine · 25
PDF
Metabolic Control by S6 Kinases Depends on Dietary Lipids
2012 · Tamara R. Castañeda, William Abplanalp, et al. · PLoS ONE · 23
PDF
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma
2019 · Nicolas Floc'h, Susan Ashton, et al. · Molecular Cancer Therapeutics · 22
PDF
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
2021 · Larissa S. Carnevalli, Molly A. Taylor, et al. · Molecular Cancer Therapeutics · 21
PDF
Phosphorylation of translation initiation factor eIF2α in the brain during pilocarpine-induced status epilepticus in mice
2004 · Larissa S. Carnevalli, Cátia M. Pereira, et al. · Neuroscience Letters · 21
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
2024 · Samar Elorbany, Chiara Berlato, et al. · Nature Communications · 20
Works count: 139
Citation count: 1,836
H-index: 22
I10-index: 27
Year
Topic
Type